Permanent Capital Management LP bought a new position in shares of Aura Biosciences, Inc. (NASDAQ: AURA) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 147,769 shares of the company's stock, valued at approximately $913,000. Permanent Capital Management LP

BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:50 a.m. ET.

Aura Biosciences, Inc. (NASDAQ: AURA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have issued a buy recommendation and one

Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint

ROAD TOWN, British Virgin Islands, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (NASDAQ: AUGO; B3: AURA33) (“Aura” ou “Companhia”) Announces to the holders of the Company's Brazilian Depositary Receipts ("BDRs") the launch of the Incentive Program for the conversion of BDRs into common shares (“Incentive Program”), under which holders may request the conversion of their BDRs (“AURA33”) into the underlying common shares (“AUGO”) listed on Nasdaq (“common shares”), at a ratio of three to one, without being required to pay the applicable fees charged by Banco Bradesco. The Incentive Program will be available for a fixed period of 32 days, from October 6, 2025, to November 6, 2025 (“Subsidy Period”).

There is no impact to the capital costs or economic results. The only change is a slightly revised all-in sustaining cost for the "Base Case" from $1,152 to $1,172 per gold ounce.

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025, at 11:00 a.m. ET.

Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC)

BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up to 3,571,435 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant, and accompanying warrants to purchase up to 892,858 shares of its common stock. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase 0.25 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying common stock warrant has an exercise price of $4.90 per share, is immediately exercisable from the date of issuance and will expire five years from the date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $4.90. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $4.89999.

BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying warrants to purchase shares of its common stock. All of the shares of common stock, pre-funded warrants and accompanying common stock warrants to be sold in the offering will be offered by Aura. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.